Actively Recruiting

Phase Not Applicable
Age: 22Years +
All Genders
NCT07119229

A Multi Center Study Testing a New Implant for Adults With Severe Emphysema

Led by Pulmair Medical, Inc. · Updated on 2026-05-08

60

Participants Needed

4

Research Sites

83 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

A study taking place at multiple sites in the United States, Europe and Brazil to evaluate how well a new therapy for severe COPD/emphysema works, and how safe it is.

CONDITIONS

Official Title

A Multi Center Study Testing a New Implant for Adults With Severe Emphysema

Who Can Participate

Age: 22Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Signed informed consent.
  • Diagnosis of COPD or emphysema.
  • At least 22 years of age.
  • Body mass index (BMI) between 18 and 32.
  • Six-minute walk distance between 100 meters and 400 meters at baseline.
  • Stable disease with less than 10 mg prednisone (or equivalent) daily.
  • Non-smoking for 4 months prior to screening, including tobacco, vaping, and marijuana.
  • Forced expiratory volume in 1 second (FEV1) between 15% and 50% of predicted value at baseline.
  • FEV1/forced vital capacity (FVC) less than 70%.
  • At least 25% emphysema destruction score in each lung determined by CT scan.
  • Homogeneous or heterogeneous emphysema with at least 15% difference between upper and lower lobes in one lung.
  • Residual volume (RV) greater than 175% of predicted value.
  • Modified Medical Research Council (mMRC) score of 2 or higher.
Not Eligible

You will not qualify if you...

  • Currently participating in another clinical study involving surgery, interventional, or pharmaceutical treatment.
  • Alpha-1 antitrypsin deficiency.
  • Women of child-bearing potential.
  • More than 2 COPD exacerbations requiring hospitalization in the past year.
  • COPD exacerbations requiring hospitalization within 6 weeks before planned intervention.
  • Two or more pneumonia episodes requiring hospitalization in the past year.
  • Clinically significant mucus production or chronic bronchitis.
  • Myocardial infarction or unstable/uncontrolled congestive heart failure within 6 months.
  • Prior lung transplant, lung volume reduction surgery, bullectomy, lobectomy, or endoscopic lung volume reduction.
  • Clinically significant bronchiectasis.
  • Unable to safely stop anti-coagulants or platelet inhibitors for 7 days.
  • Uncontrolled pulmonary hypertension or history of cor pulmonale.
  • Suspected malignant pulmonary nodule or lung cancer.
  • Large bullae over 30% of either lung, insufficient landmarks for CT evaluation, or less than 25% diseased lung parenchyma in all lobes.
  • Any cardiac condition compromising safety after IAB implant.
  • Total lung capacity less than 100% predicted.
  • Diffusing capacity of the lung for carbon monoxide (DLCO) less than 15% or greater than 50% predicted.
  • Partial pressure of carbon dioxide (PaCO2) over 50 mm Hg.
  • Partial pressure of oxygen (PaO2) less than 45 mm Hg in room air.
  • Plasma cotinine level over 13.7 ng/ml or carboxyhemoglobin over 2.5%.
  • Current diagnosis of substance abuse disorder.
  • Current diagnosis of major depressive disorder, schizoaffective disorder, schizophrenia, borderline personality disorder, or bipolar disorder.
  • Any other condition making the patient unsuitable or interfering with study participation as judged by the investigator.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 4 locations

1

University of California, San Francisco

San Francisco, California, United States, 94143

Not Yet Recruiting

2

University of California, San Francisco

San Francisco, California, United States, 94143

Actively Recruiting

3

Northwestern University

Chicago, Illinois, United States, 60611

Actively Recruiting

4

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States, 02215

Not Yet Recruiting

Loading map...

Research Team

V

VP Clincal Operations

CONTACT

C

Clinical Study Manager

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here